JP2019520341A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019520341A5 JP2019520341A5 JP2018562995A JP2018562995A JP2019520341A5 JP 2019520341 A5 JP2019520341 A5 JP 2019520341A5 JP 2018562995 A JP2018562995 A JP 2018562995A JP 2018562995 A JP2018562995 A JP 2018562995A JP 2019520341 A5 JP2019520341 A5 JP 2019520341A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- subject
- pharmaceutical composition
- disease
- ntcp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610370442 | 2016-05-30 | ||
| CN201610370442.4 | 2016-05-30 | ||
| PCT/CN2017/086558 WO2017206898A1 (en) | 2016-05-30 | 2017-05-31 | Compositions and methods for treating metabolic diseases |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019520341A JP2019520341A (ja) | 2019-07-18 |
| JP2019520341A5 true JP2019520341A5 (enExample) | 2020-07-02 |
| JP7684788B2 JP7684788B2 (ja) | 2025-05-28 |
Family
ID=60479717
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018562995A Active JP7684788B2 (ja) | 2016-05-30 | 2017-05-31 | 代謝疾患を治療する組成物と方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US11633454B2 (enExample) |
| EP (1) | EP3463422B1 (enExample) |
| JP (1) | JP7684788B2 (enExample) |
| KR (1) | KR102627084B1 (enExample) |
| CN (1) | CN109310737B (enExample) |
| AU (1) | AU2017274094B2 (enExample) |
| CA (1) | CA3026140A1 (enExample) |
| DK (1) | DK3463422T3 (enExample) |
| ES (1) | ES2979305T3 (enExample) |
| WO (1) | WO2017206898A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20240058393A1 (en) * | 2020-12-28 | 2024-02-22 | Md Healthcare Inc. | Composition comprising micrococcus luteus-derived extracellular vesicle for prevention or treatment of metabolic disease |
| KR102605753B1 (ko) * | 2021-08-06 | 2023-11-29 | 주식회사 동운아나텍 | 인공지능 기반의 혈당 예측 시스템 및 방법 |
| CN116621944A (zh) * | 2022-02-10 | 2023-08-22 | 成都奥达生物科技有限公司 | 一种长效肝炎病毒进入抑制剂 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102675430B (zh) * | 2005-08-12 | 2014-08-27 | 上海贺普药业股份有限公司 | 乙型肝炎病毒表面l蛋白相关肽 |
| CN104130316B (zh) * | 2005-08-12 | 2017-04-19 | 上海贺普药业股份有限公司 | 乙型肝炎病毒表面l蛋白相关肽 |
| CN102241744B (zh) * | 2010-05-14 | 2015-03-04 | 上海贺普药业股份有限公司 | 一种病毒感染阻断剂、其药物组合物及其应用 |
| US10413585B2 (en) * | 2012-11-12 | 2019-09-17 | Ruprecht-Karls-Universität Heidelberg | Lipopeptides for use in treating liver diseases and cardiovascular diseases |
| MX383664B (es) * | 2012-12-27 | 2025-03-14 | Ngm Biopharmaceuticals Inc | Uso de un péptido para modular la homeostasis de los ácidos biliares o tratamiento de una enfermedad relacionada con los ácidos biliares. |
| ES2922883T3 (es) | 2014-10-07 | 2022-09-21 | Myr Gmbh | Tratamiento combinado de la infección por VHB y VHD |
| EP3181146A1 (en) | 2015-12-16 | 2017-06-21 | Ruprecht-Karls-Universität Heidelberg | Cyclic ntcp-targeting peptides and their uses as entry inhibitors |
| EP3189850A1 (en) | 2015-12-16 | 2017-07-12 | Ruprecht-Karls-Universität Heidelberg | Liver targeting of cyclic pres-derived peptides of hbv |
-
2017
- 2017-05-31 KR KR1020187037955A patent/KR102627084B1/ko active Active
- 2017-05-31 JP JP2018562995A patent/JP7684788B2/ja active Active
- 2017-05-31 CN CN201780033504.5A patent/CN109310737B/zh active Active
- 2017-05-31 ES ES17805843T patent/ES2979305T3/es active Active
- 2017-05-31 WO PCT/CN2017/086558 patent/WO2017206898A1/en not_active Ceased
- 2017-05-31 AU AU2017274094A patent/AU2017274094B2/en active Active
- 2017-05-31 CA CA3026140A patent/CA3026140A1/en active Pending
- 2017-05-31 DK DK17805843.4T patent/DK3463422T3/da active
- 2017-05-31 US US16/305,790 patent/US11633454B2/en active Active
- 2017-05-31 EP EP17805843.4A patent/EP3463422B1/en active Active
-
2023
- 2023-04-06 US US18/296,454 patent/US20230414706A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102599942B1 (ko) | Hbv 및 hdv 감염의 조합 치료법 | |
| JP2013514323A5 (enExample) | ||
| CN104781274B (zh) | 用于治疗肝脏疾病和心血管疾病的脂肽 | |
| JP2017531613A5 (enExample) | ||
| JP2020535138A5 (enExample) | ||
| JP2019523648A5 (enExample) | ||
| US20230414706A1 (en) | Compositions and methods for treating metabolic diseases | |
| Chen et al. | The delivery of HBcAg via Tat-PTD enhances specific immune response and inhibits Hepatitis B virus replication in transgenic mice | |
| JP2019507182A5 (enExample) | ||
| Liu et al. | Biodistribution, activation, and retention of proinsulin-transferrin fusion protein in the liver: mechanism of liver-targeting as an insulin prodrug | |
| JP2013531681A5 (enExample) | ||
| JP2025503152A (ja) | 慢性ｂ型肝炎のヌクレオシド（ヌクレオチド）類薬物の治療を有限化する薬物及び方法 | |
| Papatheodoridis et al. | Real-world experience from tenofovir alafenamide use in chronic hepatitis B: an Hellenic multicenter real-life clinical study (HERACLIS-TAF) | |
| Robinson et al. | Investigational drugs targeting HDL-C metabolism and reverse cholesterol transport | |
| Jeon et al. | Glucagon-like Peptide-1 Receptor Agonists | |
| JP2021523214A5 (enExample) | ||
| JPWO2023053384A5 (enExample) | ||
| Tashiro et al. | 3P-0767 Relationship of plasma preβ1-HDL levels and atherosclerotic phases of coronary artery disease | |
| HK40012348B (en) | Pharmaceutical composition for preventing or treating hepatitis, hepatic fibrosis, and hepatic cirrhosis comprising fusion proteins |